These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 11712800)

  • 1. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
    Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
    Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
    Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
    Chang SM; Xing RD; Zhang FM; Duan YQ
    Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
    Hebbar M; Révillion F; Louchez MM; Vilain MO; Fournier C; Bonneterre J; Peyrat JP
    Clin Cancer Res; 1998 Feb; 4(2):373-80. PubMed ID: 9516925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy].
    Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
    Gan No Rinsho; 1989 Apr; 35(5):581-6. PubMed ID: 2541272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.